Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune-related adverse events; here, we described thrombocytopenia secondary todurvalumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218317 | PMC |
| http://dx.doi.org/10.1002/ccr3.4227 | DOI Listing |
Publication Analysis
Top Keywords
thrombocytopenia secondary
8
drug-induced immune-mediated
4
immune-mediated thrombocytopenia
4
secondary durvalumab
4
durvalumab immunotherapy
4
immunotherapy expanding
4
expanding area
4
area cancer
4
cancer treatment
4
treatment promise
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!